Biotechnology company Moderna, Inc. (NASDAQ: MRNA) Thursday reported a sharp decline in revenues for the second quarter of 2024.
- Second-quarter revenues decreased to $241 million from $344 million in the prior-year period
- Net loss narrowed to $1.28 billion or $3.33 per share in Q2 from $1.38 billion or $3.62 per share a year earlier
- Net product sales for the quarter were $184 million, reflecting a 37% decrease from the same period in 2023
- For fiscal 2024, the company expects total product sales to be between $3.0 billion and $3.5 billion
- Full-year cost of sales is expected to be in the range of 40-50% of product sales
- Q2 cost of sales was $115 million, including third-party royalties unutilized manufacturing capacity & wind-down costs, and inventory write-downs
- Cash, cash equivalents, and investments as of June 30, 2024, were $10.8 billion, vs. $12.2 billion as of March 31, 2024
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Accenture (ACN) to report Q2 2025 results Thursday. Here’s what to expect
Accenture plc, (NYSE: ACN) is preparing to publish its second-quarter results this week, amid expectations for a year-over-year increase in revenue and profit. The professional services company had a strong
What to expect when Dollar Tree (DLTR) reports Q4 2024 earnings results
Shares of Dollar Tree, Inc. (NASDAQ: DLTR) gained over 1% on Monday. The stock has dropped 6% over the past three months. The discount store chain is scheduled to report
MU Earnings Preview: Strong Q2 results in cards amid growing AI demand
Micron Technology, Inc. (NASDAQ: MU) is uniquely positioned to capitalize on the AI wave sweeping the tech industry, leveraging its high-bandwidth-memory products designed for massive data processing tasks. The company
